Treatment of Chronic Lyme Disease

Standard Treatment Approaches for Lyme Disease

• The Infectious Diseases Society of America recommends doxycycline (100 mg twice daily for adults) as a first-line treatment for uncomplicated Lyme disease without neurological involvement 1, 2
• The Infectious Diseases Society of America recommends amoxicillin (500 mg three times daily for adults) as an alternative first-line option, especially for children under 8 years and pregnant women 1, 2
• The Infectious Diseases Society of America recommends cefuroxime axetil (500 mg twice daily for adults) as another effective oral option 1, 2

Parenteral Therapy for Neurological Involvement

• The Infectious Diseases Society of America recommends intravenous ceftriaxone (2 g once daily) as the preferred parenteral regimen for neurological manifestations 1, 3
• Alternative parenteral options include cefotaxime (2 g IV every 8 hours) or penicillin G (18-24 million units per day IV divided every 4 hours), as recommended by the Infectious Diseases Society of America 1, 3

Management of Persistent Symptoms

• For patients with persistent moderate neurological manifestations after completing initial therapy, the Infectious Diseases Society of America suggests considering intravenous ceftriaxone at 2 g once daily for 14-28 days 3
• The response to treatment for late neurologic manifestations is typically slow and may be incomplete, according to the Infectious Diseases Society of America 3

Important Considerations and Pitfalls

• The Infectious Diseases Society of America strongly recommends against long-term antibiotic therapy, pulsed-dosing, combination antimicrobials, and other unproven approaches due to lack of efficacy and potential for harm 1, 2
• The Infectious Diseases Society of America recommends against using first-generation cephalosporins (e.g., cephalexin), fluoroquinolones, carbapenems, vancomycin, metronidazole, and tinidazole as they are ineffective against B. burgdorferi 1, 2
• The Infectious Diseases Society of America suggests that macrolides (e.g., azithromycin, clarithromycin) are less effective than other antibiotics and should only be used when patients cannot tolerate first-line agents 2
• The Infectious Diseases Society of America recommends considering co-infections with Babesia microti or Anaplasma phagocytophilum in patients with persistent symptoms despite appropriate therapy 1, 3

Evidence Quality and Limitations

• The Infectious Diseases Society of America strongly recommends against combination antibiotic therapy for Lyme disease, based on high-quality evidence 1, 2

Retesting for Lyme Disease After Doxycycline Treatment

Understanding Post-Treatment Testing

• Serologic tests for Lyme disease often remain positive for months or years after successful treatment, making them unreliable for determining cure or ongoing infection 4, 5
• Antibody levels do not correlate with clinical response to therapy and should not be used to monitor treatment response 6, 7
• The Infectious Diseases Society of America (IDSA) strongly recommends against routine follow-up testing after completing appropriate antibiotic therapy 4

When to Consider Retesting

• Retesting should only be considered in cases of persistent objective signs of disease activity, such as arthritis, meningitis, or neuropathy that could indicate treatment failure 4, 8
• Retesting may be considered in cases of suspected reinfection in patients with new erythema migrans lesions or new objective manifestations of Lyme disease after previous successful treatment 7
• Evaluation for possible co-infections should be considered in patients with persistent fever or characteristic laboratory abnormalities (e.g. low blood cell count) 9

Appropriate Management of Post-Treatment Symptoms

• For patients with persistent or recurring nonspecific symptoms following recommended treatment but without objective evidence of reinfection or treatment failure, additional antibiotic therapy is not recommended 4, 8
• In patients with Lyme arthritis who have partial response after initial oral antibiotic course, consider other causes of joint swelling before considering additional treatment 10, 5
• For patients with Lyme arthritis with no or minimal response to initial oral antibiotics, a 2-4 week course of IV ceftriaxone may be considered 10, 9

Important Considerations and Pitfalls

• Avoid interpreting persistent positive serology as evidence of ongoing infection; antibodies may persist for years after successful treatment 6
• Recognize that a Jarisch-Herxheimer-like reaction typically occurs only during the first 24 hours of therapy and does not indicate treatment failure 6, 11
• Be aware that long-term antibiotic therapy beyond recommended durations has not shown benefit in controlled trials and is not recommended by IDSA guidelines 11
• Consider that persistent symptoms may be due to other causes such as post-infectious phenomena, autoimmune reactions, or unrelated conditions rather than ongoing infection 8

Treatment Effectiveness Evaluation

• Clinical improvement is the most reliable indicator of treatment success, not laboratory testing 7

Management of Specific Clinical Situations in Lyme Disease

Neurological Manifestations

• In patients presenting with isolated facial (seventh cranial) nerve palsy, normal cerebrospinal fluid, and no additional neurological signs, oral antibiotic therapy is sufficient rather than intravenous treatment. 12

Co‑infection Considerations

Human Granulocytic Anaplasmosis (HGA)

• When HGA is suspected or confirmed, a 10‑day course of doxycycline (100 mg twice daily) simultaneously treats both Lyme disease and HGA. 12
• For patients unable to receive doxycycline, rifampin (300 mg twice daily for 7–10 days in adults; 10 mg/kg twice daily in children, max 300 mg per dose) can be used, but must be combined with standard oral Lyme therapy (amoxicillin or cefuroxime axetil) because rifampin does not cover Borrelia burgdorferi. 12

Babesiosis

• All individuals with active babesiosis require antimicrobial therapy to prevent serious complications. 12
• In cases of high‑grade parasitemia (≥10 %), marked hemolysis, or organ dysfunction, partial or complete red‑blood‑cell exchange transfusion is indicated. 12

Expected Treatment Response

• Clinical improvement is typically observed within 48 hours of initiating appropriate therapy for mild‑to‑moderate Lyme disease. 12
• For patients co‑infected with babesiosis, complete resolution of symptoms is expected within three months of treatment. 12